New CRISPR Therapy Shows Success in Reducing Cholesterol
新型 CRISPR 療法在降低膽固醇方面取得成功
更新於: 2026年9月29日 上午02:15
Medical science is on the brink of a revolution in treating heart disease.
醫學界正處於心臟疾病治療革命的邊緣。
Traditionally, managing high cholesterol has required patients to take daily pills or receive regular injections for their entire lives.
過去管理高膽固醇通常需要患者終身服用每日藥丸或定期注射。
However, new CRISPR-based therapies are shifting this paradigm toward a 'one-and-done' approach.
然而，基於CRISPR的新型療法正將此範式轉向「一次性治癒」的途徑。
By using precise gene-editing technology, scientists can now 'switch off' specific genes in the liver that regulate lipid levels.
透過精準的基因編輯技術，科學家現在能夠「關閉」肝臟中調節脂質水平的特定基因。
Recent trials for the therapy CTX310 have shown incredible promise.
針對CTX310療法的近期試驗展現出驚人的前景。
A single infusion successfully reduced LDL cholesterol by over 50% in patients, with results lasting at least one year and no serious safety issues reported.
單次輸注即成功將患者的低密度脂蛋白膽固醇降低了50%以上，且效果持續至少一年，且未報告嚴重安全問題。
While other treatments, like those targeting the PCSK9 gene, have faced clinical hurdles, the field remains optimistic.
儘管其他針對PCSK9基因的治療面臨臨床障礙，但該領域仍持樂觀態度。
If future trials confirm these findings, we may see a future where cardiovascular risk is managed by a single, permanent genetic adjustment rather than a lifetime of medication.
若未來試驗證實了這些發現，我們或許將迎來一個以單一永久基因調整，而非終身服藥來控制心血管風險的未來。
